Research programme: adjuvanted non-alum based anthrax vaccine - PharmAthene

Drug Profile

Research programme: adjuvanted non-alum based anthrax vaccine - PharmAthene

Alternative Names: Adjuvanted recombinant protective antigen anthrax vaccine - PharmAthene; Adjuvanted rPA anthrax vaccine - PharmAthene; DPX rPA vaccine - PharmAthene

Latest Information Update: 16 Sep 2016

Price : $50

At a glance

  • Originator PharmAthene
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Anthrax

Most Recent Events

  • 16 Sep 2016 PharmAthene plans a clinical trial for Anthrax (PharmAthene pipeline, September 2016)
  • 16 Sep 2016 PharmAthene intends to file an IND application with the U.S. Food and Drug Administration in USA for Anthrax (PharmAthene pipeline, September 2016)
  • 16 Sep 2016 Research programme: adjuvanted non-alum based anthrax vaccine - PharmAthene is available for licensing as of 16 Sep 2016. www.pharmathene.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top